The most common nonsurgical modern treatments for hyperhidrosis include topical treatments such as aluminum chloride, iontophoresis (usually with tap water), oral medications such as anticholinergics, and BTX-A. Topical treatments should always be first-line therapy. For those who fail such treatment, iontophoresis is typically recommended for those with palmar or plantar hyperhidrosis, whereas BTX is often considered as first- or second-line therapy in severe axillary hyperhidrosis. Oral anticholinergics are considered after failure of all other nonsurgical treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thorsurg.2008.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of potent topical corticosteroids versus mild ones in primary care for children with moderate flare-ups of atopic dermatitis; results of a randomised controlled trial.
BMJ Open
December 2024
Department Dermatology, Center of Pediatric Dermatology, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands.
Objective: To assess the effectiveness of a potent topical corticosteroid (TCS) as an initial treatment in primary care for children with moderate flare-ups of atopic dermatitis (AD), compared to starting on a mild TCS.
Design: An observational prospective cohort study with an embedded pragmatic multicentre open-label randomised controlled trial.
Setting: A total of 53 general practices in the southwest of the Netherlands took part in the study.
Efficacy and safety of topical cream containing aminoacryl tRNA synthetase complex interacting 1-derived peptide in mitigating radiation dermatitis after adjuvant radiotherapy for breast cancer.
Support Care Cancer
January 2025
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.
Purpose: Acute radiation dermatitis (ARD) is a frequent side effect experienced by breast cancer patients undergoing radiotherapy. This study aimed to assess the efficacy and safety of a topical cream containing aminoacryl tRNA synthetase complex interacting 1 (AIMP1)-derived peptide (AdP) in mitigating radiation dermatitis (RD) in breast cancer patients undergoing radiotherapy.
Methods: An 8-week single-center, prospective pilot study was conducted to compare the clinical efficacy and safety of an AdP-containing cream with a control cream lacking AdP for the mitigation of RD.
Biosynthesized ZnO NPs loaded-electrospun PVA/sodium alginate/glycine nanofibers: synthesis, spinning optimization and antimicrobial activity evaluation.
Sci Rep
January 2025
Chemistry Department, Faculty of Science, Menoufia University, Shibin El-Kom, 32511, Egypt.
In this work, microalgae-based zinc oxide nanoparticles loaded with electrospun polyvinyl alcohol (PVA)/sodium alginate (SA) nanofibers were fabricated by electro-spinner. PVA/SA fibrous mats were crosslinked by citric acid, which enhanced their thermal stability and swelling behavior. Green-synthesized ZnO NPs were laboratory synthesized and characterized by FTIR, XRD, EDX, SEM, TEM and TGA analyses.
View Article and Find Full Text PDFPlacebo nonresponders: An experimental investigation on their unreliability over time.
J Pain
January 2025
Innovative Clinical Training, Trials & Healthcare Initiative, Zermatt CH-3920, Switzerland.
In order to disentangle the effects of drugs from placebo responses, several approaches have been used, such as a placebo run-in phase in which only placebo nonresponders, or poor responders, are considered for further randomization to either placebo or active treatment. This study is aimed at investigating the variability of placebo nonresponders obtained through the classical placebo run-in paradigm (group RUN) and through mismatch conditioning (group MIS), as done in our previous study. To do this, we simulated a real clinical trial in the laboratory, in which the placebo responders of both groups were discarded and the remaining nonresponders of both groups RUN and MIS were randomized to either continuing on placebo (groups RUN-P and MIS-P, respectively) or receiving topical 0.
View Article and Find Full Text PDFEffectiveness of oral platelet lysate gel to treat oral mucosal manifestations associated with chronic graft versus host disease.
Blood Transfus
January 2025
Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain.
Background: Chronic graft-vs-host disease (cGvHD) is a severe immune-mediated complication that affects patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral manifestations of cGvHD, such as ulcers and mucosal inflammation, significantly impair quality of life and often require long-term treatment. Existing therapies provide limited relief, prompting the exploration of new approaches, including the use of autologous platelet lysate (PL) gel for its regenerative properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!